Skip to content

Stoke Therapeutics, Inc.

STOK Nasdaq SEC CIK 1623526

Follow Stoke Therapeutics Weekly email: filings, results, news

News

7 stories filed under Stoke Therapeutics, grouped into ongoing threads

Sells

Thread · 3 stories

Stoke Therapeutics’ director Kaye sells $402,528 in shares

Markets 37 d ago

Stoke Therapeutics general counsel Allan sells $91,639 in stock

Markets 37 d ago

Stoke therapeutics CMO Barry Ticho sells $152k in stock

Markets 37 d ago 2 sources

More coverage

Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)

Policy 21 d ago also on BIIB

Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)

Policy 23 d ago also on BIIB

Why is Stoke Therapeutics stock gaining today?

Markets 34 d ago

Stoke Therapeutics, Inc. 2026 Q2 - Results - Earnings Call Presentation

Earnings 48 d ago

Next results

NOV1

Q2 2026 results

Sunday · estimated from the filing cadence

Profile

Headquarters: BEDFORD, MA, United States
Sector: Healthcare
Industry: Pharmaceutical Preparations

Peers

Where this page comes from

Profile · SEC EDGAR

Next results · estimated from the filing cadence (SEC EDGAR)

News · 7 stories clustered from the RSS aggregator